[Cambridge session] She Started It: A Film Screening

Add this event to your calendar:
15/06/2017 19:30 15/06/2017 22:30 Europe/London [Cambridge session] She Started It: A Film Screening Murray Edwards College , , Cambridge , CB3 0DF Johnson & Johnson Innovation, JLABS false DD/MM/YYYY
June
15
Event

[Cambridge session] She Started It: A Film Screening

Murray Edwards College , , Cambridge , CB3 0DF

June 15, 2017 from 19:30 PM to 22:30 PM (GMT)

$10 - $35




96% of venture capitalists are men1. Women still account for less than 10% of founders for high growth firms2 and earn only 12.9% of computer science degrees3. "She Started It" gives a new face to the image of the tech entrepreneur: a female face.

Join Johnson & Johnson Innovation, JLABS and the Innovation Forum for a film screening of "She Started It", a new documentary film that follows five trailblazing young female entrepreneurs through their journeys of entrepreneurship.

The movie screening will be followed by a panel discussion featuring local influential women in business. All ages are welcome!

View the trailer for the film here: https://www.youtube.com/watch?v=hcGGrUx666s

1Fortune
2"Sources of Economic Hope" by Kauffman Foundation
3Computing Research Association study



Agenda:
17:30 | Registration Opens & Networking Reception
18:30 | Film Screening of "She Started It"
19:30 | Panel Discussion
20:30 | Programme Close


Speakers:
Karin Conde-Knape | VP of Cardiovascular & Metabolism Scientific Innovation, Johnson & Johnson Innovationread bio»
Tanya Hutter | Darwin College Research Fellow at the Department of Chemistry, University of Cambridge read bio»
Fiona Nielsen | Founder and CEO, RePositive and DNAdigest read bio»


Fees:
FREE | General Public


Location:
Kaetsu Lecture Theatre
Murray Edwards College 

Speakers:
Karin Conde-Knape | VP of Cardiovascular & Metabolism Scientific Innovation, Johnson & Johnson Innovation
Karin Conde-Knape is Vice President of Scientific Innovation, Cardiovascular & Metabolic at Johnson & Johnson Innovation. In this role, her main responsibilities are to identify, evaluate, set and manage external collaborations within the CVM area in Europe, Israel and Asia Pacific bringing additional value to the Johnson and Johnson pipeline. Previously, Karin was Global Head of Discovery in the CVM DTA at Roche where she was responsible for all the Early Research efforts as well as the Translational Biomarker and experimental medicine group. While at Roche, Karin was directly or indirectly responsible for identifying and managing numerous external collaborations with well renowned institutions worldwide. In addition, throughout her career at Roche, she had several roles, including laboratory head, project leader, head of pharmacology and co-department head in the CV and Metabolism Disease and Translational Area, both in the US and in Switzerland. She was responsible for setting and implementing the pharmacology strategy for the portfolio in the CVM group in areas such as Diabetes, Atherosclerosis, Dyslipidemia, Kidney, and CV disease. Karin received her PhD in Nutritional Sciences from the University of Connecticut, and completed her post-doctoral fellowship at Columbia University.



Tanya Hutter | Darwin College Research Fellow at the Department of Chemistry, University of Cambridge
Tanya Hutter is currently a Darwin College Research Fellow at the Department of Chemistry at the University of Cambridge. Her research focuses on chemical sensors and bio-sensors. After completing her PhD in Physical Chemistry in Cambridge in 2013, she founded SensorHut to develop and commercialise a chemical sensor technology for gas detection.






Fiona Nielsen | Founder and CEO, RePositive and DNAdigest
Bioinformatics scientist specialised in genome analysis with 15 years of experience in software development and project management. Fiona left her job at Illumina Cambridge in 2013 to pursue her vision of enabling efficient genomic data sharing and founded the charity DNAdigest. In August 2014 she founded Repositive as a spin out of DNADigest.

Event Partner:



Media Partner:


Johnson & Johnson Innovation, JLABS

About Johnson & Johnson Innovation, JLABS Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries. JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property. JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and healthtech sectors. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then has grown to ten global locations including the Bay Area, Boston & Lowell, MA, Houston, Toronto, Beerse (Belgium), with New York City, opening in June 2018, and Shanghai in 2019. For more information please visit www.jlabs.jnjinnovation.com or follow @JLABS.

Event contact


Related content